Lingohr Asset Management GmbH Has $302,000 Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• Lingohr Asset Management GmbH significantly reduced its Teva Pharmaceutical stock position by 91.6%, ending the quarter with 18,000 shares valued at $302,000.
• Teva's quarterly earnings surpassed estimates, reporting $0.66 EPS on a revenue of $4.18 billion, although this was below the expected $4.34 billion.
• Various institutional investors are actively modifying their holdings, with notable increases from Ion Asset Management and Harel Insurance Investments, indicating strong interest in Teva stocks.

Lingohr Asset Management GmbH reduced its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 91.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,000 shares of the company's stock after selling 197,159 shares during the period. Lingohr Asset Management GmbH's holdings in Teva Pharmaceutical Industries were worth $302,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Ion Asset Management Ltd. grew its stake in shares of Teva Pharmaceutical Industries by 6.5% during the first quarter. Ion Asset Management Ltd. now owns 39,033,500 shares of the company's stock worth $599,945,000 after buying an additional 2,383,500 shares during the last quarter. Menora Mivtachim Holdings LTD. increased its holdings in Teva Pharmaceutical Industries by 2.8% in the first quarter. Menora Mivtachim Holdings LTD. now owns 29,189,316 shares of the company's stock valued at $448,640,000 after purchasing an additional 808,074 shares during the period. Migdal Insurance & Financial Holdings Ltd. increased its holdings in Teva Pharmaceutical Industries by 1.2% in the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,335,422 shares of the company's stock valued at $404,775,000 after purchasing an additional 300,000 shares during the period. Harel Insurance Investments & Financial Services Ltd. increased its holdings in Teva Pharmaceutical Industries by 197,885.2% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 22,055,547 shares of the company's stock valued at $338,989,000 after purchasing an additional 22,044,407 shares during the period. Finally, Duquesne Family Office LLC increased its holdings in Teva Pharmaceutical Industries by 65.4% in the first quarter. Duquesne Family Office LLC now owns 14,879,750 shares of the company's stock valued at $228,702,000 after purchasing an additional 5,882,350 shares during the period. Institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Price Performance

TEVA stock opened at $19.96 on Monday. The stock has a market capitalization of $22.89 billion, a PE ratio of -124.75, a price-to-earnings-growth ratio of 1.16 and a beta of 0.72. The company's 50-day moving average is $17.31 and its 200-day moving average is $16.50. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.64 by $0.02. The company had revenue of $4.18 billion for the quarter, compared to analysts' expectations of $4.34 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The business's revenue was up .3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.61 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. Equities research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Eric A. Hughes sold 52,742 shares of the business's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $799,568.72. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Placid Jover sold 6,053 shares of the business's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $91,763.48. Following the completion of the transaction, the insider owned 6,774 shares in the company, valued at $102,693.84. The trade was a 47.19% decrease in their position. The disclosure for this sale can be found here. 0.55% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the company. Truist Financial assumed coverage on Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They issued a "buy" rating and a $25.00 price objective for the company. The Goldman Sachs Group assumed coverage on Teva Pharmaceutical Industries in a report on Friday, June 6th. They issued a "buy" rating and a $24.00 price objective for the company. Wall Street Zen upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. Finally, UBS Group decreased their price objective on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating for the company in a report on Thursday, June 26th. Two investment analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $24.71.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.